FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4286295501> ?p ?o ?g. }

• W4286295501 endingPage "4093" @default.
• W4286295501 startingPage "4093" @default.
• W4286295501 abstract "4093 Background: Early-stage hepatocellular carcinoma (HCC) can be treated with liver resection (LR), but up to 70% of patients experience relapse within two years after surgery. Despite their established use in advanced disease, immune checkpoint inhibitors (ICPI) are still under investigation in the peri-operatory setting. Methods: PRIME‐HCC is a phase Ib study investigating safety and bioactivity of the nivolumab (3 mg/kg, day 1 and day 22) plus ipilimumab (1mg/kg, day 1 only) combination (Nivo+Ipi) prior to LR in early-stage HCC. The primary safety analysis assessed treatment-related adverse events (trAE) and delays to surgery. Secondary endpoint included objective response rate (ORR) by RECIST v1.1 and pathologic response rate on resection specimens. Results: At data censoring on the 27 th of January 2022, 17 patients were enrolled, of whom 82% (n = 14) were male, with a median age of 64 years (range 47-76). Performance status was 0 in 88% of patients (n = 15) according to the Eastern Cooperative Oncology Group scale. Liver cirrhosis was found in 65% (n = 11) of the patients, mostly secondary to viral hepatitis (41%, n = 7). All patients were Child-Pugh A, with 53% (n = 9) classified as albumin-bilirubin (ALBI) grade 2, and the rest grade 1. Median tumour diameter was 3.4 cm (interquartile range [IQR] 2.4-4.0), and the median number of liver nodules was 1 (range 1-3). Any-grade trAEs were reported by 73% of the patients receiving at least one dose of treatment (n = 11, tot n = 15). Four patients (27%) reported grade 2 trAEs including hypothyroidism (n = 2), diarrhoea (n = 1), and fatigue (n = 1), and one (7%) grade 3 ALT/AST elevation. After a median follow-up of 6.3 months (IQR 1.9-23.0), no deaths had occurred. One patient had experienced relapse 20.8 months after treatment commencement, and he achieved partial response to subsequent treatment with atezolizumab plus bevacizumab. Median time to LR from screening was 2.5 months (IQR 2.3-3.2). Only one patient had a surgery delay due to liver function worsening (ICPI-unrelated) and experienced disease progression 12.4 months post-screening. One patient was found to have cholangiocarcinoma (CCA) on LR specimen and was excluded from efficacy analyses. Of the 13 patients with an available radiological assessment, ORR was 23%, with two partial responses and one complete response. Disease control rate was 92%, with one patient with mixed HCC/CCA histology showing primary progression. Of the nine pathologically evaluable patients, seven (78%) achieved a pathological response, including two (22%) complete responses. Conclusions: Nivo+Ipi can be safely administered in the neoadjuvant setting for HCC and does not delay LR. The combination demonstrates promising evidence of anti-tumour efficacy in terms of radiological and pathological response. Clinical trial information: NCT03682276." @default.
• W4286295501 created "2022-07-21" @default.
• W4286295501 creator A5003890551 @default.
• W4286295501 creator A5007167001 @default.
• W4286295501 creator A5009737345 @default.
• W4286295501 creator A5020147308 @default.
• W4286295501 creator A5022765346 @default.
• W4286295501 creator A5023635260 @default.
• W4286295501 creator A5025777431 @default.
• W4286295501 creator A5040305234 @default.
• W4286295501 creator A5047800429 @default.
• W4286295501 creator A5051093023 @default.
• W4286295501 creator A5052244421 @default.
• W4286295501 creator A5053323102 @default.
• W4286295501 creator A5060429192 @default.
• W4286295501 creator A5060954139 @default.
• W4286295501 creator A5078706966 @default.
• W4286295501 creator A5079017840 @default.
• W4286295501 creator A5081707339 @default.
• W4286295501 date "2022-06-01" @default.
• W4286295501 modified "2023-09-25" @default.
• W4286295501 title "Preliminary results from a phase Ib study of neoadjuvant ipilimumab plus nivolumab prior to liver resection for hepatocellular carcinoma: The PRIME-HCC trial." @default.
• W4286295501 doi "https://doi.org/10.1200/jco.2022.40.16_suppl.4093" @default.
• W4286295501 hasPublicationYear "2022" @default.
• W4286295501 type Work @default.
• W4286295501 citedByCount "4" @default.
• W4286295501 countsByYear W42862955012023 @default.
• W4286295501 crossrefType "journal-article" @default.
• W4286295501 hasAuthorship W4286295501A5003890551 @default.
• W4286295501 hasAuthorship W4286295501A5007167001 @default.
• W4286295501 hasAuthorship W4286295501A5009737345 @default.
• W4286295501 hasAuthorship W4286295501A5020147308 @default.
• W4286295501 hasAuthorship W4286295501A5022765346 @default.
• W4286295501 hasAuthorship W4286295501A5023635260 @default.
• W4286295501 hasAuthorship W4286295501A5025777431 @default.
• W4286295501 hasAuthorship W4286295501A5040305234 @default.
• W4286295501 hasAuthorship W4286295501A5047800429 @default.
• W4286295501 hasAuthorship W4286295501A5051093023 @default.
• W4286295501 hasAuthorship W4286295501A5052244421 @default.
• W4286295501 hasAuthorship W4286295501A5053323102 @default.
• W4286295501 hasAuthorship W4286295501A5060429192 @default.
• W4286295501 hasAuthorship W4286295501A5060954139 @default.
• W4286295501 hasAuthorship W4286295501A5078706966 @default.
• W4286295501 hasAuthorship W4286295501A5079017840 @default.
• W4286295501 hasAuthorship W4286295501A5081707339 @default.
• W4286295501 hasConcept C119060515 @default.
• W4286295501 hasConcept C121608353 @default.
• W4286295501 hasConcept C126322002 @default.
• W4286295501 hasConcept C143998085 @default.
• W4286295501 hasConcept C197934379 @default.
• W4286295501 hasConcept C203092338 @default.
• W4286295501 hasConcept C207103383 @default.
• W4286295501 hasConcept C2777214474 @default.
• W4286295501 hasConcept C2777701055 @default.
• W4286295501 hasConcept C2778019345 @default.
• W4286295501 hasConcept C2780030458 @default.
• W4286295501 hasConcept C2781433595 @default.
• W4286295501 hasConcept C44249647 @default.
• W4286295501 hasConcept C535046627 @default.
• W4286295501 hasConcept C71924100 @default.
• W4286295501 hasConcept C90924648 @default.
• W4286295501 hasConceptScore W4286295501C119060515 @default.
• W4286295501 hasConceptScore W4286295501C121608353 @default.
• W4286295501 hasConceptScore W4286295501C126322002 @default.
• W4286295501 hasConceptScore W4286295501C143998085 @default.
• W4286295501 hasConceptScore W4286295501C197934379 @default.
• W4286295501 hasConceptScore W4286295501C203092338 @default.
• W4286295501 hasConceptScore W4286295501C207103383 @default.
• W4286295501 hasConceptScore W4286295501C2777214474 @default.
• W4286295501 hasConceptScore W4286295501C2777701055 @default.
• W4286295501 hasConceptScore W4286295501C2778019345 @default.
• W4286295501 hasConceptScore W4286295501C2780030458 @default.
• W4286295501 hasConceptScore W4286295501C2781433595 @default.
• W4286295501 hasConceptScore W4286295501C44249647 @default.
• W4286295501 hasConceptScore W4286295501C535046627 @default.
• W4286295501 hasConceptScore W4286295501C71924100 @default.
• W4286295501 hasConceptScore W4286295501C90924648 @default.
• W4286295501 hasIssue "16_suppl" @default.
• W4286295501 hasLocation W42862955011 @default.
• W4286295501 hasOpenAccess W4286295501 @default.
• W4286295501 hasPrimaryLocation W42862955011 @default.
• W4286295501 hasRelatedWork W2766588635 @default.
• W4286295501 hasRelatedWork W2899127460 @default.
• W4286295501 hasRelatedWork W2947988614 @default.
• W4286295501 hasRelatedWork W3005150264 @default.
• W4286295501 hasRelatedWork W3175085288 @default.
• W4286295501 hasRelatedWork W3207731879 @default.
• W4286295501 hasRelatedWork W4205224142 @default.
• W4286295501 hasRelatedWork W4206770832 @default.
• W4286295501 hasRelatedWork W4242728034 @default.
• W4286295501 hasRelatedWork W4377100578 @default.
• W4286295501 hasVolume "40" @default.
• W4286295501 isParatext "false" @default.
• W4286295501 isRetracted "false" @default.
• W4286295501 workType "article" @default.